<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376243</url>
  </required_header>
  <id_info>
    <org_study_id>Earlyemollient Version 2.0</org_study_id>
    <nct_id>NCT03376243</nct_id>
  </id_info>
  <brief_title>EARLYEMOLLIENT - Feasibility of Early Emollient Use in Children With Atopic Eczema</brief_title>
  <acronym>EARLYemo</acronym>
  <official_title>A Pilot Study to Determine the Feasibility of Early Emollient Use in Children With High Risk for Atopic Eczema - EARLYemollient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pragmatic, parallel group, assessor-blind randomised open-label prospective&#xD;
      study is to determine the reasons that motivate parents to enrol or not enrol their child in&#xD;
      a randomized, controlled basic emollient trial for the prevention of atopic eczema (AE).&#xD;
      Furthermore, this trial intends to test the hypothesis that daily skin barrier enhancement&#xD;
      with Lipikar Baume AP+® in newborns at high risk is safe and efficient in preventing AE.&#xD;
&#xD;
      T&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this trial is to determine the reasons that motivate parents to enrol or not enrol&#xD;
      their child in a randomized, controlled basic emollient trial for the prevention of AE.&#xD;
      Furthermore, this trial intends to test the hypothesis that daily skin barrier enhancement&#xD;
      with Lipikar Baume AP+® in babies at high risk of allergic disease is safe and to estimate&#xD;
      the preventive effectiveness of Lipikar Baume AP+® in the prevention of AE in a high risk&#xD;
      population.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The primary objectives are to investigate the&#xD;
&#xD;
        1. Feasibility:&#xD;
&#xD;
             1. Parental willingness to enter a child in a controlled primary prevention trial&#xD;
&#xD;
             2. Compliance with intervention&#xD;
&#xD;
        2. Safety: incidence of skin-related adverse events and serious adverse events during the&#xD;
           study&#xD;
&#xD;
        3. Effectiveness:&#xD;
&#xD;
             1. Cumulative incidence of AE within 2 years after randomization.&#xD;
&#xD;
             2. Age of onset of AE&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Pragmatic, parallel group, assessor-blind randomised open-label prospective study of&#xD;
      emollient use in 50 high-risk neonates starting between days 1 and 21. Child participation in&#xD;
      the main part of the trial will be 2 years (from within 3 weeks of birth until approximately&#xD;
      the child's second birthday). This will comprise a 1 year intervention phase then the primary&#xD;
      outcome is assessed at 2 years.&#xD;
&#xD;
      Participants:&#xD;
&#xD;
      Participants will be newborn babies at high risk of developing AE defined as a parent or&#xD;
      sibling who has (or had) doctor diagnosed asthma, AE or allergic rhinitis.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      The intervention is daily application of emollient to the baby's entire body surface area&#xD;
      including the face for the first year of life. Intervention and control group will receive&#xD;
      structured parent education that comprises general advice on best practice skin care for&#xD;
      their baby in line with the German AWMF S3 guidelines for allergy prevention and the Federal&#xD;
      Centre for Health Education.&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      Infants will be examined at scheduled visits at Months 1, 6, 12, and 24. Telephone visits&#xD;
      were performed at months 3 and 18 to assess for side effects, rashes, and compliance. Daily&#xD;
      parental recordings will be assessed using electronic data capturing tools.&#xD;
&#xD;
      Primary Outcomes:&#xD;
&#xD;
      The primary outcomes will be feasibility, safety and tolerability, and preventive&#xD;
      effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Willingness to participate</measure>
    <time_frame>2 years</time_frame>
    <description>Willingness of parents to get their child randomized and to adhere to the regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of AE</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transepidermal water loss</measure>
    <time_frame>2 years</time_frame>
    <description>Development of transepidermal water loss over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome diversity</measure>
    <time_frame>2 years</time_frame>
    <description>Development of microbiome diversity over time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Emollient (LIPIKAR BAUME AP+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of Lipikar Baume AP+ emollient AND Structured parent education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only structured parent education</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LIPIKAR BAUME AP+ emollient</intervention_name>
    <description>Structured education on prevention guidelines</description>
    <arm_group_label>Emollient (LIPIKAR BAUME AP+)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant (i.e. the newborn baby) must have a parent or sibling with a history of&#xD;
             AE, allergic rhinitis or asthma.&#xD;
&#xD;
          -  Infant in overall good health.&#xD;
&#xD;
          -  Term-born babies&#xD;
&#xD;
          -  Mother at least 18 years of age at delivery and capable of giving informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preterm birth (defined as birth prior to 37 weeks gestation).&#xD;
&#xD;
          -  Previous child randomised to this trial.&#xD;
&#xD;
          -  Major congenital anomaly.&#xD;
&#xD;
          -  Significant inflammatory skin disease at birth (except seborrheic dermatitis).&#xD;
&#xD;
          -  Any immunodeficiency disorder or severe genetic skin disorder.&#xD;
&#xD;
          -  Any condition that would make the use of emollients inadvisable or not possible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Weidinger, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USchleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Scheswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Stephan Weidinger</investigator_full_name>
    <investigator_title>Deputy Head, Department of Dermatology and Allergy</investigator_title>
  </responsible_party>
  <keyword>Atopic eczema, prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emollients</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

